ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
James B. McClurken
Valluvan Jeevanandam
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prendergast, T. W.
Right arrow Articles by Jeevanandam, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prendergast, T. W.
Right arrow Articles by Jeevanandam, V.

Ann Thorac Surg 1996;62:670-674
© 1996 The Society of Thoracic Surgeons

Original Articles: Cardiovascular

Defining the Role of Aprotinin in Heart Transplantation

Thomas W. Prendergast, MD, Satoshi Furukawa, MD, A. James Beyer, III, MD, Howard J. Eisen, MD, James B. McClurken, MD, Valluvan Jeevanandam, MD

Division of Cardiothoracic Surgery, University of Kansas Medical Center, Kansas City, Kansas, and Sections of Cardiothoracic Surgery and Cardiology, Temple University Health Sciences Center, Philadelphia, Pennsylvania

Background. Heart transplantation is associated with excessive bleeding due to recipient coagulopathy, frequent need for reoperative median sternotomy, and prolonged cardiopulmonary bypass. Aprotinin reduces bleeding and the inflammatory response after cardiopulmonary bypass, but there are concerns about efficacy and side effects.

Methods. To determine the role of aprotinin in primary and reoperative sternotomy heart transplantation, we studied 70 patients undergoing heart transplantation between August 1993 and October 1994. Thirty-eight undergoing primary sternotomy for heart transplantation and receiving no aprotinin were randomized to group A (n = 20); patients in group B (n = 18) received the full recommended dose. Similarly, 32 patients undergoing reoperative heart transplantation were randomized to group C (n = 16), receiving no aprotinin, and to group D (n = 16), receiving aprotinin at the full recommended dose. All patients received the same immunosuppression regimen. Similarities in the groups included recipient age, weight, preoperative hemodynamic indices, creatinine, creatinine clearance, platelet count, hemoglobin, percentage receiving warfarin, prothrombin time, partial thromboplastin time, cardiopulmonary bypass time, and creatinine level at 48 hours.

Results. There were no significant differences postoperatively between groups A and B. Differences (p < 0.05) 24 hours postoperatively between groups C and D, respectively, included: total blood product requirement (5.9 ± 3.8 versus 3.6 ± 2.0 U), total fluid balance (+752 ± 300 versus -250 ± 185 mL), chest tube drainage (894 ± 120 versus 526 ± 95 mL), alveolar-arterial O2 difference (120.4 ± 45.9 versus 95.5 ± 33.5), and pulmonary artery mean pressures (28.2 ± 4.6 versus 21.1 ± 3.5 mm Hg).

Conclusions. Aprotinin decreases bleeding after reoperative heart transplantation without renal dysfunction. Decreased inflammation is manifested as reduced fluid requirement and improved pulmonary and right heart function, which benefit patients during the posttransplantation period. Aprotinin at recommended doses is effective and safe for patients undergoing reoperative heart transplantation.




This article has been cited by other articles:


Home page
 Eur. J. Cardiothorac. Surg.Home page
J. H. Shuhaiber, K. Goldsmith, S. R. Large, and S. Tsui
Does perioperative use of aprotinin reduce the rejection rate in heart transplant recipients?
Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 849 - 855.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
A. M. Mahdy and N. R. Webster
Perioperative systemic haemostatic agents
Br. J. Anaesth., December 1, 2004; 93(6): 842 - 858.
[Abstract] [Full Text] [PDF]

Home page
 J Intensive Care MedHome page
R. S. Poston and B. P. Griffith
Heart Transplantation
J Intensive Care Med, January 1, 2004; 19(1): 3 - 12.
[Abstract] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
J. A. Quin, M. P. Tauriainen, L. M. Huber, D. D. McIntire, P. A. Kaiser, W. S. Ring, and M. E. Jessen
Predictors of pericardial effusion after orthotopic heart transplantation
J. Thorac. Cardiovasc. Surg., November 1, 2002; 124(5): 979 - 983.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
C. D. Morris, J. D. Vega, J. H. Levy, N. N. Buist, A. L. Smith, G. J. Despotis, and K. R. Kanter
Warfarin therapy does not increase bleeding in patients undergoing heart transplantation
Ann. Thorac. Surg., September 1, 2001; 72(3): 714 - 718.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. M. Mannucci
Hemostatic Drugs
N. Engl. J. Med., July 23, 1998; 339(4): 245 - 253.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
T. L. Spray
Use of Aprotinin in Pediatric Organ Transplantation
Ann. Thorac. Surg., June 1, 1998; 65(90060): S71 - 73.
[Abstract] [Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
D. Royston
Hemostatic Drugs in Prothrombotic or Hypercoagulable States
Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 376 - 394.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
T. Carrel, J. Neth, P. Mohacsi, A. Gallino, and M. I. Turina
Perioperative Risk and Long-Term Results of Heart Transplantation After Previous Cardiac Operations
Ann. Thorac. Surg., April 1, 1997; 63(4): 1133 - 1137.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1996 by The Society of Thoracic Surgeons.